Tag: clinical

New clinical cleanroom manufacturing and training facility launches in Brisbane

The Hon Karen Andrews, Minister for Industry, Science and Technology is opening the Translational Research Institute’s (TRI) new state-of-the-art clinical cleanroom manufacturing and training facility, T3 Cleanrooms, and the inaugural MTPCareers Symposium on Wednesday 14 October 2020.

The new cleanroom facility will help significantly speed-up the translation of Australian medical innovations into clinical practice, and will be available to researchers, start-ups and companies to manufacture sterile products on a small scale.

Professor Scott Bell, CEO of the TRI says the T3 Cleanroom facility is the outcome of a successful partnership with Australian biotech, Vaxxas Pty Ltd, to secure funding from MTPConnect to build clinical manufacturing and training capacity.

Based in dedicated commercial space at TRI, Vaxxas worked with us to identify a critical gap in medtech manufacturing and skills for companies needing to scale-up production for clinical trials, which led TRI

Read More

Alec Baldwin Backs New Invisi Smart Mask, Cutting Edge Technology, Endorsed By Clinical Test And Scientist That Kills 99.99% Of SARS CoV-2 Germs

During a Pandemic it is important to STAY SAFE and be able to LIVE LIFE. Invisi Smart is an engineered next-generation solution that kills 99.99% of SARS CoV-2 germs. It provides your loved ones, people, healthcare professionals, athletes and businesses with long-lasting invisible protection. Invisi Smart technology is verified by robust laboratory and clinical evidence, and comes as a Mask, Shield Spray, Seat Covers, and Sanitizer. It is important to note that Invisi Smart is a long-lasting product that doesn’t use carcinogens.

Invisi Smart Technologies has been proven to destroy the COVID-19 spike virus by the University of Cambridge. “We found that the products are active and effectively inhibited infection by an enveloped VIRUS-bearing SARS-CoV-2 Spike protein on its surface, with a viral core and genome based on lentivirus,” said Ravindra K. Gupta, Professor of Clinical Microbiology, University of Cambridge, UK.

When asked why he got involved,

Read More

Alec Baldwin Backs New Invisismart Mask, Cutting Edge Technology, Endorsed By Clinical Test And Scientist That Kills 99.99% Of SARS CoV-2 Germs

During a Pandemic it is important to STAY SAFE and be able to LIVE LIFE. InvisiSmart is an engineered next-generation solution that kills 99.99% of SARS CoV-2 germs. It provides your loved ones, people, healthcare professionals, athletes and businesses with long-lasting invisible protection.

InvisiSmart technology is verified by robust laboratory and clinical evidence, and comes as a Mask, Shield Spray, Seat Covers, and Sanitizer. It is important to note that InvisiSmart is a long lasting product that doesn’t use carcinogens.

INVISISMART Technologies has been proven to destroy the COVID-19 spike virus by the University of Cambridge. “We found that the products are active and effectively inhibited infection by an enveloped VIRUS-bearing SARS-CoV-2 Spike protein on its surface, with a viral core and genome based on lentivirus”, said Ravindra K. Gupta, Professor of Clinical Microbiology, University of Cambridge, UK.

Most recently, the explosive White House Coronavirus Outbreak brought

Read More

I’m in a Covid-19 vaccine clinical trial to honor my father, fight racism and exercise my power

My dad, Timothy L. Pernell Sr., believed in science. But as a Black man coming of age in the Jim Crow South, the path to his career as a research scientist was convoluted, taking twists and turns because of the barriers too often cemented in place by racism.

After a two-week bout with the illness, his heroic story ended. It was unlike what we’d imagined his ending would be — but nonetheless his was a life sealed in triumph.

As a student he excelled, but college proved too high a hurdle for his family in 1959 Richmond, Virginia, so he dreamt of becoming a Navy fighter pilot instead. After taking a qualifying exam at the recruiting station, he was led to believe he failed. Thinking his dreams were dashed, he left Virginia for New York to find opportunity elsewhere — following a migration route that many Blacks traveled. After his

Read More

Abby Abraham Joins George Clinical to lead Global Data Science and head India Business

Abby Abraham Joins George Clinical to lead Global Data Science and head India Business

PR Newswire

OVERLAND PARK, Kan., Oct. 8, 2020

OVERLAND PARK, Kan., Oct. 8, 2020 /PRNewswire/ — Abby Abraham, a veteran clinical researcher and data science lead, has joined George Clinical, a global scientifically-backed clinical research organization, to head up the organization’s Global Data Science team and operations in India.

George Clinical Science. Service. Solutions. (PRNewsfoto/George Clinical)
George Clinical Science. Service. Solutions. (PRNewsfoto/George Clinical)

Abraham, a progressive clinical research professional passionate about altering the existing clinical research execution paradigm by bringing together competent and engaged people, brings George Clinical a deep knowledge of novel technologies and smart data processes.  He has more than 20 years of experience in the clinical technology industry working with global CROs including progression through multiple roles within clinical operations and general management.

“I am very pleased and delighted to welcome Abby to George Clinical to head up

Read More

Capillary Biomedical Receives $1.5 Million from Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology

IRVINE, Calif.–(BUSINESS WIRE)–Capillary Biomedical, Inc. (CapBio) has announced that it has received a $1.5 million program-related investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley). The use of funds includes clinical studies of CapBio’s novel SteadiFlowtm technology to evaluate the potential for extended-wear of insulin infusion sets by people with Type 1 diabetes for 7 days and beyond.

CapBio’s SteadiSettm infusion set, powered by its SteadiFlow technology platform, is designed to increase the wear time of insulin infusion sets by addressing the common causes of infusion site failure. Infusion sets are a key component of recently introduced automated insulin delivery (AID) systems that use continuous glucose monitoring (CGM) sensors to guide insulin pump therapy. Sets are designed to be changed every two to three days, but sites often fail sooner. Infusion site failures can lead to diabetic

Read More

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics

A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for solid tumor cancer patients, today announced the closing of its $71.5M Series B financing. Proceeds will fund the advancement of its Tmod (T-cell module) platform and the clinical development and in-house manufacturing of its three near-term product candidates. Tmod-engineered T cells uniquely combine a potent activating mechanism to kill tumor cells with a blocking mechanism that protects normal cells from harm by exploiting the loss of genetic material in tumors. “We are the first company to create robust engineered T cells that can integrate two signals in this way, harnessing the awesome power of immune cells to attack tumors that have lost specific genes, while sparing normal cells whose genomes are intact,” said Scott Foraker, president and chief executive officer of A2.

The Tmod design and proof-of-concept work was published last Friday in Molecular Immunology (Hamburger et al., 2020).

Read More

‘Dating site technology’ to help heart failure patients find clinical trials

A UK charity for heart failure patients has developed a website which uses matching technology often used for dating sites to pair patients with appropriate clinical trials.

The Pumping Marvellous Foundation has launched the website, called cardiotrials.org, to mark World Heart Day in an effort to change how trials are recruited for and increase access to care.

The charity says it hopes the system can help take the pressure off the NHS by no longer relying on healthcare staff to identify potential patients suitable for trials.

The new website will allow patients to see what trials are currently running as well as match them to trials that suit their needs and requirements.

Heart failure expert Professor Mark Petrie, from Glasgow University, said the new system was a “huge step forward”.

He added: “That patients can now volunteer to join heart failure trials is fantastic. Specialist heart failure teams can now

Read More

‘Dating site technology’ to help heart failure patients find clinical trials

A UK charity for heart failure patients has developed a website which uses matching technology often used for dating sites to pair patients with appropriate clinical trials.

The Pumping Marvellous Foundation has launched the website, called cardiotrials.org, to mark World Heart Day in an effort to change how trials are recruited for and increase access to care.

The charity says it hopes the system can help take the pressure off the NHS by no longer relying on healthcare staff to identify potential patients suitable for trials.

The new website will allow patients to see what trials are currently running as well as match them to trials that suit their needs and requirements.

Heart failure expert Professor Mark Petrie, from Glasgow University, said the new system was a “huge step forward”.

He added: “That patients can now volunteer to join heart failure trials is fantastic. Specialist heart failure teams can now

Read More

Anova Expands Technology Platform Providing Patients With Access to Any Clinical Trial or Promising Treatment Wherever They Receive Care

LONDON & CHICAGO–(BUSINESS WIRE)–Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating clinical development with the industry’s first collaborative ‘learning system,’ today announced the expansion of AnovaOS™, a technology platform that brings investigators, sites, patients and biopharmaceutical companies together to accelerate development of promising new treatments. The platform improves trial access for sites, physicians and patients and reduces the time and cost of recruitment, enrolment and study conduct for sponsors.

The biopharmaceutical industry faces a perfect storm, including increasing drug development timelines, rising R&D cost, decreasing return on R&D investment, increasing clinical trial complexity, increasing regulatory burden and conflicted development partners, leading to rising treatment cost that threatens to bankrupt the entire system.

At the same time, demand for clinical trials is increasing as the industry transitions from blockbuster to precision medicine products, mergers and acquisitions underperform, advances in personalized medicine (“omics”) increase the number of druggable targets

Read More